Capricor Therapeutics, Inc. (CAPR) stock
CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.24−0.98 (-8.73%)
Close on Nov 12, 2026Market cap $595.34MP/E –Yield –
Capricor Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Capricor Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$151.06M. For fiscal 2025 it was -$106.25M. The highest annual figure on record is -$2.08M in fiscal 2012.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$106.25M | – |
| FY2024 | Dec 31, 2024 | -$41.14M | – |
| FY2023 | Dec 31, 2023 | -$23.01M | – |
| FY2022 | Dec 31, 2022 | -$29.16M | – |
| FY2021 | Dec 31, 2021 | -$20.69M | – |
| FY2020 | Dec 31, 2020 | -$13.55M | – |
| FY2019 | Dec 31, 2019 | -$7.56M | – |
| FY2018 | Dec 31, 2018 | -$15.17M | – |
| FY2017 | Dec 31, 2017 | -$12.72M | – |
| FY2016 | Dec 31, 2016 | -$16.85M | – |
| FY2015 | Dec 31, 2015 | -$12.50M | – |
| FY2014 | Dec 31, 2014 | -$5.98M | – |
| FY2013 | Dec 31, 2013 | -$6.88M | – |
| FY2012 | Dec 31, 2012 | -$2.08M | – |
| FY2011 | Dec 31, 2011 | -$4.89M | – |
| FY2010 | Dec 31, 2010 | -$6.28M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$43.78M | – |
| Q2 FY2026 | Jun 30, 2026 | -$42.38M | – |
| Q1 FY2026 | Mar 31, 2026 | -$36.24M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$25.79M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.23M | – |
| Q1 FY2025 | Mar 31, 2025 | -$24.58M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.32M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.65M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.93M | – |
| Q4 FY2023 | Dec 31, 2023 | -$973.68K | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.59M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.49M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.95M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.34M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.21M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.74M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.30M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.25M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.03M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.14M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.88M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.46M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.07M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.44M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.58M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.02M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.26M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.13M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.12M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.65M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.25M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.60M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.34M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.53M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.88M | – |
See a number that looks wrong?